PTC Therapeutics Inc. said early Monday that it plans to launch the Duchenne muscular dystrophy drug Emflaza at a price of $35,000 a year and within the coming weeks. The price tag comes in below the controversial $89,000-a-year price set by Emflaza's previous owner, privately-held Marathon Pharmaceuticals, which faced so much backlash on the drug's price tag that it delayed Emflaza's launch. The price tag was especially controversial because the drug is part of a class of corticosteroids...READ FULL ARTICLE »
Become a member to take advantage of more features, like commenting and voting.
Register or sign in today!